PMID- 32299269
OWN - NLM
STAT- MEDLINE
DCOM- 20220215
LR  - 20220501
IS  - 1471-1753 (Electronic)
IS  - 0954-6634 (Linking)
VI  - 33
IP  - 1
DP  - 2022 Feb
TI  - Indirect comparisons of ixekizumab versus three interleukin-23 p19 inhibitors in 
      patients with moderate-to-severe plaque psoriasis - efficacy findings up to week 
      12.
PG  - 54-61
LID - 10.1080/09546634.2020.1747592 [doi]
AB  - BACKGROUND: It is challenging to select the most appropriate biologic treatment 
      for patients with moderate-to-severe plaque psoriasis. OBJECTIVE: To compare 
      speed of onset and level of skin improvement between the interleukin (IL)-17A 
      antagonist ixekizumab and the IL-23 p19 inhibitors guselkumab, tildrakizumab, and 
      risankizumab in patients with moderate-to-severe plaque psoriasis. METHODS: Using 
      data from controlled clinical trials, both adjusted indirect comparisons (AICs) 
      and matching adjusted indirect comparisons (MAICs) were performed to determine 
      the risk difference (RD) between ixekizumab and each IL-23 p19 inhibitor for the 
      proportion of patients with >/=75%/90%/100% improvement compared with baseline in 
      Psoriasis Area and Severity Index (PASI 75/90/100) up to week 12. Placebo, 
      etanercept, or ustekinumab were used as the comparator bridge. RESULTS: In all 
      (M)AICs, RDs generally significantly favored ixekizumab over guselkumab (placebo 
      bridge), tildrakizumab (placebo or etanercept bridge), and risankizumab (placebo 
      or ustekinumab bridge) from the earliest assessment time (>/= week 2) to week 12 
      when considering PASI 75/90/100 responses. CONCLUSION: Ixekizumab provides a 
      faster onset of effect and earlier clinical benefits than guselkumab, 
      tildrakizumab, or risankizumab in patients with moderate-to-severe psoriasis, as 
      reflected by higher levels of skin improvement than with these IL-23 p19 
      inhibitors up to week 12.
FAU - Gottlieb, Alice B
AU  - Gottlieb AB
AD  - Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, 
      USA.
FAU - Saure, Daniel
AU  - Saure D
AD  - Eli Lilly & Company, Indianapolis, IN, USA.
FAU - Wilhelm, Stefan
AU  - Wilhelm S
AD  - Eli Lilly & Company, Indianapolis, IN, USA.
FAU - Dossenbach, Martin
AU  - Dossenbach M
AD  - Eli Lilly & Company, Indianapolis, IN, USA.
FAU - Schuster, Christopher
AU  - Schuster C
AD  - Eli Lilly & Company, Indianapolis, IN, USA.
FAU - Smith, Saxon D
AU  - Smith SD
AUID- ORCID: 0000-0003-0995-4372
AD  - Discipline of Dermatology, Northern Sydney Medical School, University of Sydney, 
      Sydney, NSW, Australia.
AD  - Department of Dermatology, Royal North Shore Hospital, St Leonards, NSW, 
      Australia.
FAU - Ramot, Yuval
AU  - Ramot Y
AUID- ORCID: 0000-0002-8606-8385
AD  - Department of Dermatology, Hadassah Medical Center, Hebrew University of 
      Jerusalem, The Faculty of Medicine, Jerusalem, Israel.
FAU - Thaci, Diamant
AU  - Thaci D
AD  - Institute and Comprehensive Center for Inflammation Medicine, University of 
      Lubeck, Lubeck, Germany.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200417
PL  - England
TA  - J Dermatolog Treat
JT  - The Journal of dermatological treatment
JID - 8918133
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Interleukin-23)
RN  - 0 (Interleukin-23 Subunit p19)
RN  - BTY153760O (ixekizumab)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized
MH  - Humans
MH  - *Interleukin-23
MH  - Interleukin-23 Subunit p19
MH  - *Psoriasis/drug therapy
MH  - Severity of Illness Index
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Ixekizumab
OT  - indirect comparison
OT  - interleukin-23 inhibitors
OT  - psoriasis
EDAT- 2020/04/18 06:00
MHDA- 2022/02/16 06:00
CRDT- 2020/04/18 06:00
PHST- 2020/04/18 06:00 [pubmed]
PHST- 2022/02/16 06:00 [medline]
PHST- 2020/04/18 06:00 [entrez]
AID - 10.1080/09546634.2020.1747592 [doi]
PST - ppublish
SO  - J Dermatolog Treat. 2022 Feb;33(1):54-61. doi: 10.1080/09546634.2020.1747592. 
      Epub 2020 Apr 17.